Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant

Université Laval

$153,000.00

Multi-pathway cholesterol depletion on top of FOLFIRINOX in newly diagnosed metastatic pancreatic adenocarcinoma: a feasibility and proof-of-concept study

EF 2018-19

Résumé
According to the Canadian Cancer Statistics, out of 100 patients diagnosed with pancreatic cancer, only 8 will still be alive 5 years later. Most patients will die within the first year after diagnosis. Given this very poor survival, there is an urgent need for new treatments that will prolong survival and hopefully cure pancreatic cancer. Recent studies have shown that pancreatic cancer needs cholesterol to progress. Cutting cholesterol supplies could slow or even stop pancreatic cancer progression while sensitizing the tumor to chemotherapy. Given that powerful, well tolerated and affordable cholesterol-lowering drugs are now available and routinely used in patients with heart diseases, it is indicated to verify if these safe drugs can also treat patients with pancreatic cancer. The current project is to verify whether adding cholesterol-lowering drugs on top of current cancer therapies is feasible. To answer this question, a small number of patients newly diagnosed with pancreatic cancers will be given a combination of cholesterol-lowering drugs with chemotherapy. Many data will be collected, including acceptability of the treatment, observed adverse effects and more. These preliminary data are needed to proceed to future tolerability, safety and efficacy studies. Pancreatic cancer is not the only cancer that requires cholesterol to thrive. There are indications that cancers such as breast, prostate, colon, kidney, melanoma and many others rewire their metabolism in order to secure abundant cholesterol supplies. There is a possibility that besieging tumors with a sustained cholesterol blockade combined with chemotherapy and/or immunotherapy could translate into increased survival in many cancers and bring us closer to a cure.
Programme
Project Grant
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
402794
Name
Gangloff Anne
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Cancer Progression & Therapeutics 2
Projecttitle
Multi-pathway cholesterol depletion on top of FOLFIRINOX in newly diagnosed metastatic pancreatic adenocarcinoma: a feasibility and proof-of-concept study
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$153,000
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Acceptability Of The Regimen; Biomarkers (Lipid Profile, Tumoral Ldlr, Npc1l1, Srb1); Cholesterol-Lowering Drugs (Pcsk9 Inh, Statins, Ezetimibe); Clinical Trial (Non-Randomized, Open-Label); Dose-Limiting Toxicities; Estimates Of Progression-Free Survival; Estimates To Perform Power Calculation; Feasibility And Proof-Of-Concept Study; Folfirinox; Metastatic Pancreatic Ductal Adenocarcinoma
Abstract
According to the Canadian Cancer Statistics, out of 100 patients diagnosed with pancreatic cancer, only 8 will still be alive 5 years later. Most patients will die within the first year after diagnosis. Given this very poor survival, there is an urgent need for new treatments that will prolong survival and hopefully cure pancreatic cancer. Recent studies have shown that pancreatic cancer needs cholesterol to progress. Cutting cholesterol supplies could slow or even stop pancreatic cancer progression while sensitizing the tumor to chemotherapy. Given that powerful, well tolerated and affordable cholesterol-lowering drugs are now available and routinely used in patients with heart diseases, it is indicated to verify if these safe drugs can also treat patients with pancreatic cancer. The current project is to verify whether adding cholesterol-lowering drugs on top of current cancer therapies is feasible. To answer this question, a small number of patients newly diagnosed with pancreatic cancers will be given a combination of cholesterol-lowering drugs with chemotherapy. Many data will be collected, including acceptability of the treatment, observed adverse effects and more. These preliminary data are needed to proceed to future tolerability, safety and efficacy studies. Pancreatic cancer is not the only cancer that requires cholesterol to thrive. There are indications that cancers such as breast, prostate, colon, kidney, melanoma and many others rewire their metabolism in order to secure abundant cholesterol supplies. There is a possibility that besieging tumors with a sustained cholesterol blockade combined with chemotherapy and/or immunotherapy could translate into increased survival in many cancers and bring us closer to a cure.
Competitiondate
201903
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Gangloff, Anne
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $153,000~ $0~